Introduction
Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR | BSE: 544252), one of India’s premier fast-moving consumer healthcare (FMCH) and over-the-counter (OTC) pharmaceutical enterprises, announced its standalone financial results for the first quarter of fiscal year 2026-27 (Q1 FY27) on July 28, 2026. The company delivered a quarter marked by strong domestic volume recovery, pricing discipline, and operational leverage.
For equity investors tracking consumer health and fast-moving consumer goods (FMCG) sub-sectors, Sanofi Consumer Healthcare’s quarterly update highlights a structural shift. Despite export market drag on a high historical base, the company expanded its EBITDA margins by 611 basis points YoY to 37.9%. Net profit after tax expanded to ₹68.8 crore from ₹60.7 crore in the year-ago period.
The main growth driver for the quarter was a 12% YoY surge in domestic sales. This was fueled by strong consumer demand across flagship brands like Allegra, Combiflam, DePURA, and Avil, alongside brand re-promotions in urban retail and digital commerce platforms. With zero long-term debt, robust cash generation, and a multi-channel distribution push, Sanofi Consumer Healthcare India continues to demonstrate fundamental strength in the consumer health landscape.
SANOFICONR Q1 FY27 FINANCIAL HIGHLIGHTS SNAPSHOT
=============================================================================
* Revenue from Operations : ₹235.70 Cr (+6.70% YoY)
* Standalone EBITDA : ₹ 89.30 Cr (+27.21% YoY)
* EBITDA Margin : 37.89% (Expanded 611 bps YoY)
* Profit Before Tax (PBT) : ₹ 91.90 Cr (+16.48% YoY)
* Net Profit After Tax : ₹ 68.80 Cr (+13.34% YoY)
* Basic & Diluted EPS : ₹ 29.87 (+13.32% YoY)
* Domestic Business Growth : +12.00% YoY (Fueled by relaunches & market share)
=============================================================================
Company Overview
History & Strategic De-merger
Sanofi Consumer Healthcare India Limited was incorporated following the strategic corporate de-merger of the Consumer Healthcare (CHC) business unit from Sanofi India Limited. The transaction was structured to create a dedicated, agile entity focused on fast-moving consumer healthcare, over-the-counter wellness products, and self-care solutions across India.
Business Model & Industry Segment
Sanofi Consumer Healthcare operates at the intersection of consumer fast-moving consumer goods (FMCG) and classical pharmaceuticals. The company’s business model centers on self-care, wellness promotion, pain management, allergy relief, and digestive health.
+---------------------------------------+
| SANOFI CONSUMER HEALTHCARE INDIA LTD |
+-------------------+-------------------+
|
+----------------------------------+----------------------------------+
| |
v v
+---------------------------------+ +---------------------------------+
| DOMESTIC CONSUMER HEALTHCARE | | EXPORT & CONTRACT BUSINESS |
+---------------------------------+ +---------------------------------+
| - Pain Care (Combiflam Family) | | - Contract Manufacturing |
| - Allergy Care (Allegra, Avil) | | - Inter-company Global Supply |
| - Wellness & VMS (DePURA) | | - Regional Export Markets |
| - Digestive Health (Festal) | | |
+---------------------------------+ +---------------------------------+
Key Brands & Competitive Position
The company holds market positions across several core therapeutic categories:
Allergy Care: Allegra (fexofenadine) and Avil (pheniramine maleate) serve as market leaders in non-drowsy and classical antihistamine formulations.
Pain Care: Combiflam (ibuprofen + paracetamol) is a household brand name in oral analgesics and topical pain relief gels.
Vitamin & Mineral Supplements (VMS): DePURA (Vitamin D3 drops and oral solutions) addresses preventative bone health needs.
Digestive Wellness: Festal serves as an established brand in enzyme-based digestive aids.
Q1 FY27 Financial Highlights
The following table presents the official standalone financial results for Sanofi Consumer Healthcare India Limited for the first quarter ended June 30, 2026 (Q1 FY27) compared against historical comparative quarters:
Standalone Financial Performance Table
| Financial Metric (₹ in Crore) | Q1 FY27 (Actual) | Q1 FY26 (Actual) | YoY Change (%) | Q4 FY26 (Actual) | QoQ Change (%) |
| Revenue from Operations | 235.70 | 220.90 | +6.70% | 229.20 | +2.84% |
| Material Costs Consumed | 68.30 | 79.50 | -14.09% | 66.80 | +2.25% |
| Employee Expense | 31.20 | 29.80 | +4.70% | 30.50 | +2.30% |
| Other Operating Expenses | 46.90 | 41.40 | +13.29% | 43.10 | +8.82% |
| Total Expenses | 146.40 | 150.70 | -2.85% | 140.40 | +4.27% |
| EBITDA | 89.30 | 70.20 | +27.21% | 88.80 | +0.56% |
| EBITDA Margin (%) | 37.89% | 31.78% | +611 bps | 38.74% | -85 bps |
| Depreciation & Amortisation | 3.20 | 2.80 | +14.29% | 3.10 | +3.23% |
| Other Income | 5.80 | 11.50 | -49.57% | 6.20 | -6.45% |
| Finance Cost | 0.00 | 0.00 | 0.00% | 0.00 | 0.00% |
| Profit Before Tax (PBT) | 91.90 | 78.90 | +16.48% | 91.90 | 0.00% |
| Tax Expense | 23.10 | 18.20 | +26.92% | 23.10 | 0.00% |
| Net Profit After Tax (PAT) | 68.80 | 60.70 | +13.34% | 68.80 | 0.00% |
| Basic & Diluted EPS (₹) | 29.87 | 26.36 | +13.32% | 29.87 | 0.00% |
| Gross Margin (%) | 71.02% | 63.92% | +710 bps | 70.86% | +16 bps |
| Net Profit Margin (%) | 29.19% | 27.48% | +171 bps | 30.02% | -83 bps |
(Source: Company Exchange Filings, Press Releases, & Financial Data)
Segment-wise & Revenue Performance
Sanofi Consumer Healthcare India operates as a single reportable operating segment—Consumer Healthcare. However, analyzing revenue by distribution channel and market geography reveals clear underlying business momentum:
Domestic Sales vs Export Sales Breakdown - Q1 FY27
=============================================================================
Domestic Business Growth : +12.0% YoY (Fueled by retail push & product relaunches)
Export Business Growth : -9.0% YoY (Impacted by a high base in Q1 FY26)
Total Revenue Growth : +6.7% YoY (Consolidated net top-line expansion)
=============================================================================
1. Domestic Consumer Health Business (+12% YoY)
The domestic business serves as the core revenue driver for the enterprise. Domestic revenues grew by 12% YoY in Q1 FY27, benefiting from:
Product Relaunch Gains: Full-year market share recovery in products that underwent voluntary precautionary recalls in 2024.
Commercialization in E-Commerce: Strong growth in quick-commerce and digital pharmacy channels for OTC brands like Allegra and DePURA.
Seasonal Demand: Early onset of seasonal allergies and monsoons driving demand for antihistamines (Allegra, Avil) and pain management care (Combiflam).
2. Export & Contract Manufacturing (-9% YoY)
Export revenues declined 9% YoY during the quarter. This contraction was primarily attributed to a high historical base in Q1 FY26, alongside scheduled inventory realignments by international parent affiliates.
Brand-wise Performance & Growth Catalysts
Allegra Family: Maintained brand leadership in the prescription-to-OTC allergy segment. Brand extensions like Allegra-M and child-friendly syrup formulations drove volume expansion.
Combiflam: Recorded mid-double-digit growth across oral solid formulations and topical pain sprays, supported by marketing campaigns around everyday pain management.
DePURA Vitamin D3: Capitalized on preventative healthcare trends in urban India, securing pharmacy recommendations.
Avil: Continued to provide steady, recurring cash flow within classical allergy therapies.
Margin & Profitability Analysis
The standout metric from Sanofi Consumer Healthcare’s Q1 FY27 performance was the expansion in operational profit margins:
EBITDA Margin Expansion Trend (Q1 FY26 to Q1 FY27)
-----------------------------------------------------------------------------
Q1 FY26 : [EBITDA Margin: 31.78%] ===========================>
Q4 FY26 : [EBITDA Margin: 38.74%] ======================================>
Q1 FY27 : [EBITDA Margin: 37.89%] =====================================>
-----------------------------------------------------------------------------
Key Drivers of 611 bps Margin Expansion
Raw Material Price Tailwinds: Softening active pharmaceutical ingredient (API) prices and lower key starting material (KSM) costs drove gross margins up 710 bps YoY to 71.02%.
Favorable Product Mix: A higher ratio of high-margin domestic branded formulations relative to low-margin bulk exports boosted realization per unit.
Operating Leverage: Fixed employee and overhead costs expanded at a slower pace (+2.85% decrease in total operating expenses YoY), allowing incremental gross profit to flow to operating EBITDA.
Balance Sheet & Working Capital Check
Sanofi Consumer Healthcare India operates a net-cash balance sheet with minimal capital expenditure requirements.
Cash and Liquidity: Maintained a strong cash and bank balance position, supporting future inorganic brand acquisitions or higher dividend payouts.
Working Capital Trajectory: Operating cash flow for H1 FY27 improved sharply to ₹109.6 crore (up from ₹17.9 crore in H1 FY26). Free cash flow for H1 FY27 reached ₹108.8 crore.
Working Capital Build: Trade receivables rose to ₹49.8 crore (up 68% YoY) and inventories expanded to ₹93.7 crore (up 51.4% YoY), reflecting seasonal channel stocking to support domestic demand ahead of peak monsoons.
Financial Ratio Analysis
The financial ratio profile underscores Sanofi Consumer Healthcare’s operational efficiency and return metrics:
Key Financial Ratios Summary
| Ratio Parameter | Q1 FY27 Value | Q1 FY26 Value | Financial Interpretation |
| Return on Equity (ROE – TTM) | ~71.60% | ~65.20% | High equity return profile due to asset-light model. |
| Return on Capital Employed (ROCE) | ~89.90% | ~80.10% | Strong capital efficiency with net-cash balance sheet. |
| Price-to-Earnings (P/E Ratio) | 41.1x | 44.5x | Trades in line with Indian MNC consumer healthcare peers. |
| EBITDA Margin (%) | 37.89% | 31.78% | Expanded 611 bps YoY due to gross margin expansion. |
| Net Profit Margin (%) | 29.19% | 27.48% | Healthy conversion of top-line revenue into net profit. |
| Debt-to-Equity Ratio | 0.00 (Zero Debt) | 0.00 | Debt-free balance sheet ensuring financial flexibility. |
| Asset Turnover Ratio | 2.15x | 2.05x | High revenue generation on low fixed asset base. |
Management Commentary & Earnings Takeaways
During the Q1 FY27 financial results release, executive leadership highlighted operational strategy:
Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Ltd:
“Our performance this quarter reflects disciplined execution across all fronts. Our targeted investments behind our brands and go-to-market capabilities are translating into profitable growth and market share gains in most of our brands, reinforcing our confidence in our strategy. Domestic demand remains resilient, and the continued recovery of our relaunched portfolio confirms consumer trust in our brands.”
Conference Call & Business Highlights
Demand Outlook: Management expects domestic consumer healthcare demand to remain resilient, supported by urban wellness trends and rural penetration.
Go-to-Market Strategy: Expanding direct pharmacy coverage and partnering with quick-commerce channels for OTC brands.
Export Normalization: Export business expected to stabilize in H2 FY27 as parent affiliate inventory levels normalize.
Share Price Reaction & Market Data
Following the announcement of Q1 FY27 financial results on July 28, 2026, Sanofi Consumer Healthcare India’s stock traded with a positive bias on the NSE and BSE.
SANOFICONR Stock Trading Snapshot (July 29, 2026 Data)
=============================================================================
Current Market Price (CMP) : ₹4,744.00 per share
52-Week High : ₹5,512.00
52-Week Low : ₹3,950.00
Market Capitalization : ₹10,944 Crore
Trailing P/E Ratio : 41.1x
Dividend Yield : 1.56%
Price-to-Book (P/B) Ratio : ~31.4x (Reflecting asset-light model)
=============================================================================
Peer Comparison
The table below benchmarks Sanofi Consumer Healthcare India against key listed peers in the Indian healthcare and consumer care space:
Peer Comparison Table
| Company Name | Market Cap (₹ Cr) | Trailing P/E | EBITDA Margin (%) | PAT Margin (%) | ROCE (%) | ROE (%) |
| Sanofi Consumer Healthcare | 10,944 | 41.1x | 37.89% | 29.19% | 89.90% | 71.60% |
| P&G Health Ltd. | ~14,200 | ~38.5x | ~32.50% | ~22.10% | ~45.20% | ~36.80% |
| Abbott India Ltd. | ~62,500 | ~48.2x | ~24.80% | ~18.50% | ~38.40% | ~31.20% |
| GlaxoSmithKline Pharma | ~48,000 | ~52.1x | ~26.10% | ~19.20% | ~42.10% | ~33.50% |
| Hindustan Unilever (FMCG) | ~5,80,000 | ~56.4x | ~23.50% | ~17.20% | ~35.60% | ~29.40% |
SWOT Analysis
+-----------------------------------------------------------------------------------+
| SANOFI CONSUMER HEALTHCARE INDIA SWOT |
+---------------------------------------------------+-------------------------------+
| STRENGTHS | WEAKNESSES |
| - High-equity OTC brands (Allegra, Combiflam)| - High short-term inventory |
| - Exceptional EBITDA margins (37.9%) | and receivable build|
| - Debt-free balance sheet with cash reserves| - Reliance on export parent |
| - Superior return ratios (ROCE >89%) | affiliate orders|
+---------------------------------------------------+-------------------------------+
| OPPORTUNITIES | THREATS |
| - RX-to-OTC switch expansion in India | - Price caps under National |
| - Digital commerce & quick-commerce scale-up | List of Essential Medicines |
| - Preventative health trends (Vitamin D3) | - Raw material cost inflation |
+---------------------------------------------------+-------------------------------+
Key Growth Drivers
Brand Extensions & Line Additions: Launching topical gels, sprays, and child-specific formulations under Combiflam and Allegra.
Digital & E-Pharmacy Channel Push: Quick-commerce partnerships providing same-day delivery for OTC allergy and pain relief products.
Preventative Healthcare Expansion: Increasing consumer awareness regarding Vitamin D deficiencies driving DePURA sales.
Operating Leverage & Asset-Light Model: High margin flow-through from incremental sales due to an outsourced manufacturing model.
Key Risks
Regulatory Pricing Controls: Inclusion of essential formulations under NLEM price caps could restrict pricing freedom.
Export Market Fluctuations: Swings in global parent orders can create temporary volatility in export revenues.
Raw Material Inflation: Spikes in API or packaging costs could compress gross margins.
Analyst View & Investment Thesis
Bull Case
Domestic sales expanding at 12% YoY with market share gains in core brands.
EBITDA margins expanding to 37.9%, supported by raw material cost tailwinds.
Net-cash balance sheet with a ROCE of ~89.9%.
Bear Case
Revenue growth of 6.7% lagging broader Indian Pharma Market (IPM) growth rates.
Working capital build-up in inventories (+51.4%) and trade receivables (+68%) requiring monitoring.
Final Verdict
Sanofi Consumer Healthcare India Limited reported a strong Q1 FY27 financial performance. Achieving 13.3% net profit growth to ₹68.8 crore and a 611 bps EBITDA margin expansion to 37.9% highlights its underlying operational execution.
While export contraction created a top-line drag, the 12% domestic sales growth confirms that consumer demand for core brands remains strong. For long-term investors seeking exposure to the high-margin, debt-free consumer healthcare market in India, SANOFICONR remains a fundamental business to track.
